Deferred Revenue

3 Months Ended

Mar. 31, 2022

Revenue From Contract With Customer [Abstract]

Deferred Revenue

4. Deferred Revenue

Deferred revenue from our Genentech Agreement represents $56.9 million and $80.9 million of the current and non-current deferred revenue balances, respectively, as of March 31, 2022 and $56.1 million and $94.0 million of the current and non-current deferred revenue balances, respectively, as of December 31, 2021. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately four to five years from March 31, 2022. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various research and development activities.

Changes in deferred revenue during the three months ended March 31, 2022 were as follows (in thousands):

Deferred revenue balance at December 31, 2021	$	179,210
Additions to deferred revenue during the period		8,907
Revenue recognized during the period		(19,719	)
Deferred revenue balance at March 31, 2022	$	168,398

As of March 31, 2022, $16.0 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2021.